This protocol isn't appropriate for patients who are pregnant or nursing, individuals under 18, those with active cancer, or patients with contraindications to GLP-1 medications (medullary thyroid carcinoma history, MEN2 syndrome, history of pancreatitis)
Most available estimates come from theoretical analysis, anecdotal interpretation, or limited animal data
(4) Notably, exposing wound models to the peptide has been linked with fewer infiltrating inflammatory cells and lower tissue levels of key inflammatory mediators such as leukotriene B4, thromboxane B2, and myeloperoxidase
Interested in GHK-Cu Therapy in New York
The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
